ABCC11 | ATP-binding cassette, sub-family C (CFTR/MRP), member 11 | Predicted membrane proteins
| | | | | Tissue enhanced |
ABCC2 | ATP-binding cassette, sub-family C (CFTR/MRP), member 2 | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
ABCC3 | ATP-binding cassette, sub-family C (CFTR/MRP), member 3 | Cancer-related genes Predicted membrane proteins Transporters
| | | | | Mixed |
ABCD3 | ATP-binding cassette, sub-family D (ALD), member 3 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
ACKR2 | Atypical chemokine receptor 2 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
AQP1 | Aquaporin 1 (Colton blood group) | Blood group antigen proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
AQP2 | Aquaporin 2 (collecting duct) | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
ATP7B | ATPase, Cu++ transporting, beta polypeptide | Cancer-related genes Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CCR7 | Chemokine (C-C motif) receptor 7 | Cancer-related genes CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CD47 | CD47 molecule | CD markers Predicted membrane proteins
| | | | | Expressed in all |
CDS2 | CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 | Enzymes Mitochondrial proteins Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
CLN6 | Ceroid-lipofuscinosis, neuronal 6, late infantile, variant | Disease related genes Predicted membrane proteins
| | | | | Expressed in all |
DERL2 | Derlin 2 | Predicted membrane proteins
| | | | | Expressed in all |
EDNRA | Endothelin receptor type A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
FADS1 | Fatty acid desaturase 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
FAIM2 | Fas apoptotic inhibitory molecule 2 | Predicted membrane proteins
| | | | | Group enriched |
GPR143 | G protein-coupled receptor 143 | Disease related genes G-protein coupled receptors Potential drug targets Predicted membrane proteins
| | | | | Mixed |
HHATL | Hedgehog acyltransferase-like | Predicted membrane proteins
| | | | | Group enriched |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNF1 | Potassium voltage-gated channel, subfamily F, member 1 | Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH1 | Potassium voltage-gated channel, subfamily H (eag-related), member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ2 | Potassium voltage-gated channel, KQT-like subfamily, member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNQ5 | Potassium voltage-gated channel, KQT-like subfamily, member 5 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
MBTPS2 | Membrane-bound transcription factor peptidase, site 2 | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Expressed in all |
MCOLN3 | Mucolipin 3 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
MLC1 | Megalencephalic leukoencephalopathy with subcortical cysts 1 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
OPRM1 | Opioid receptor, mu 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
PROM1 | Prominin 1 | CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
PROM2 | Prominin 2 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
RHCG | Rh family, C glycoprotein | Predicted membrane proteins Transporters
| | | | | Group enriched |
SFXN1 | Sideroflexin 1 | Mitochondrial proteins Predicted membrane proteins
| | | | | Expressed in all |
SFXN2 | Sideroflexin 2 | Mitochondrial proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SFXN4 | Sideroflexin 4 | Disease related genes Mitochondrial proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC13A3 | Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC17A4 | Solute carrier family 17, member 4 | Predicted membrane proteins Transporters
| | | | | Group enriched |
SLC1A5 | Solute carrier family 1 (neutral amino acid transporter), member 5 | Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC22A2 | Solute carrier family 22 (organic cation transporter), member 2 | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC2A1 | Solute carrier family 2 (facilitated glucose transporter), member 1 | Cancer-related genes Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC2A4 | Solute carrier family 2 (facilitated glucose transporter), member 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC2A9 | Solute carrier family 2 (facilitated glucose transporter), member 9 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC35D2 | Solute carrier family 35 (UDP-GlcNAc/UDP-glucose transporter), member D2 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC39A6 | Solute carrier family 39 (zinc transporter), member 6 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC44A4 | Solute carrier family 44, member 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
SLC8A2 | Solute carrier family 8 (sodium/calcium exchanger), member 2 | Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC9A1 | Solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), member 1 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLCO1B3 | Solute carrier organic anion transporter family, member 1B3 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |